Skip to main content

Advertisement

SpringerLink
Log in

Rifampin as adjuvant treatment of Gram-positive bacterial infections: a systematic review of comparative clinical trials

  • Review
  • Published:
European Journal of Clinical Microbiology & Infectious Diseases Aims and scope Submit manuscript

Abstract

We reviewed the bibliographic evidence from comparative trials regarding the role of rifampin as adjuvant treatment in the treatment of Gram-positive infections [PubMed (1/1950–7/2006)]. Only studies reporting comparative outcome data in patients treated with an antibiotic regimen with the addition or not of rifampin were included. Eight comparative studies were identified [all were randomized controlled trials (RCTs)], five reporting on infections caused by staphylococci (S. aureus in 97% of patients) and three by streptococci. There was no statistically significant difference in mortality between the treatment arms (with and without rifampin) in any of the included studies. Clinical cure was achieved more commonly (p < 0.05) in the rifampin treatment arm in 3/8 studies; in staphylococcal infections of orthopedic stable implants and in beta-hemolytic streptococcal pharyngitis in children (one RCT each), and in one RCT that reported on patients with various staphylococcal infections. However, no statistically significant difference in cure of the infection between the two groups was found after pooling data from two RCTs (121 patients) that reported on patients with various staphylococcal infections (odds ratio = 0.57; 95% confidence interval 0.27–1.17). No differences were noted between the two groups regarding relapse of infection or adverse events. There is only limited evidence from comparative trials regarding the role of rifampin as adjuvant therapeutic agent for infections caused by Gram-positive bacteria, not allowing for definitive conclusions on this important management question. More controlled trials are necessary for better evaluation of this practice.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Calderon E, Gatica R, Echaniz G et al (1991) Treatment of presumed bacterial pneumonia in ambulatory children. Clin Ther 13(6):699–706

    PubMed  CAS  Google Scholar 

  2. Falagas ME, Fragoulis KN, Bliziotis IA (2006) Oral rifampin for prevention of S. aureus carriage-related infections in patients with renal failure-a meta-analysis of randomized controlled trials. Nephrol Dial Transplant 21(9):2536–2542

    Article  PubMed  CAS  Google Scholar 

  3. Kissling M, Bergamini N (1981) Rifampicin in free combination with other antimicrobial drugs in non-Tb infections. Clinical data on 650 patients (a review). Chemotherapy 27(5):368–402

    Article  PubMed  CAS  Google Scholar 

  4. Korvick JA, Peacock JE Jr, Muder RR, Wheeler RR, Yu VL (1992) Addition of rifampin to combination antibiotic therapy for Pseudomonas aeruginosa bacteremia: prospective trial using the Zelen protocol. Antimicrob Agents Chemother 36(3):620–625

    PubMed  CAS  Google Scholar 

  5. Muder RR, Boldin M, Brennen C et al (1994) A controlled trial of rifampicin, minocycline, and rifampicin plus minocycline for eradication of methicillin-resistant Staphylococcus aureus in long-term care patients. J Antimicrob Chemother 34(1):189–190

    Article  PubMed  CAS  Google Scholar 

  6. Tanz RR, Shulman ST, Barthel MJ, Willert C, Yogev R (1985) Penicillin plus rifampin eradicates pharyngeal carriage of group A streptococci. J Pediatr 106(6):876–880

    Article  PubMed  CAS  Google Scholar 

  7. Baddour LM, Wilson WR, Bayer AS et al (2005) Infective endocarditis: diagnosis, antimicrobial therapy, and management of complications: a statement for healthcare professionals from the committee on rheumatic fever, endocarditis, and kawasaki disease, council on cardiovascular disease in the young, and the councils on clinical cardiology, stroke, and cardiovascular surgery and anesthesia, American heart association: endorsed by the infectious diseases society of America. Circulation 111:394–434

    Article  Google Scholar 

  8. Elliott TS, Foweraker J, Gould FK, Perry JD, Sandoe JA (2004) Working party of the British society for antimicrobial chemotherapy. Guidelines for the antibiotic treatment of endocarditis in adults: report of the working party of the British society for antimicrobial chemotherapy. J Antimicrob Chemother 54:971–981

    Article  PubMed  CAS  Google Scholar 

  9. Gemmell CG, Edwards DI, Fraise AP, Gould FK, Ridgway GL, Warren RE; The Joint Working Party of the British Society of Antimicrobial Chemotherapy, Hospital Infection Society and Infection Control Nurse Association (2006) Guidelines for the prophylaxis and treatment of methicillin-resistant Staphylococcus aureus (MRSA) infections in the UK. J Antimicrob Chemother 57:589–608

    Article  PubMed  CAS  Google Scholar 

  10. Archer GL, Tenenbaum MJ, Haywood HB 3rd (1978) Rifampin therapy of Staphylococcus epidermidis. Use in infections from indwelling artificial devices. JAMA 240(8):751–753

    Article  PubMed  CAS  Google Scholar 

  11. Archer GL, Johnston JL, Vazquez GJ, Haywood HB 3rd (1983) Efficacy of antibiotic combinations including rifampin against methicillin-resistant Staphylococcus epidermidis: in vitro and in vivo studies. Rev Infect Dis 5(Suppl 3):S538–S542

    PubMed  CAS  Google Scholar 

  12. Faville RJ Jr, Zaske DE, Kaplan EL, Crossley K, Sabath LD, Quie PG (1978) Staphylococcus aureus endocarditis. Combined therapy with vancomycin and rifampin. JAMA 240(18):1963–1965

    Article  PubMed  Google Scholar 

  13. Hedberg A, Hardemark HG, Olsson-Liljequist B, Sjolin J (2004) Penetration of fusidic acid and rifampicin into cerebrospinal fluid in low-grade inflammatory meningitis caused by Staphylococcus epidermidis. Clin Microbiol Infect 10(8):765–768

    Article  PubMed  CAS  Google Scholar 

  14. Chaudhary S, Bilinsky SA, Hennessy JL et al (1985) Penicillin V and rifampin for the treatment of group A streptococcal pharyngitis: a randomized trial of 10 days penicillin vs 10 days penicillin with rifampin during the final 4 days of therapy. J Pediatr 106:481–486

    Article  PubMed  CAS  Google Scholar 

  15. Klugman KP, Friedland IR, Bradley JS (1995) Bactericidal activity against cephalosporin-resistant Streptococcus pneumoniae in cerebrospinal fluid of children with acute bacterial meningitis. Antimicrob Agents Chemother 39:1988–1992

    PubMed  CAS  Google Scholar 

  16. Levine DP, Fromm BS, Reddy BR (1991) Slow response to vancomycin or vancomycin plus rifampin in methicillin-resistant Staphylococcus aureus endocarditis. Ann Intern Med 115:674–680

    PubMed  CAS  Google Scholar 

  17. Norden CW, Bryant R, Palmer D, Montgomerie JZ, Wheat J (1986) Chronic osteomyelitis caused by Staphylococcus aureus: controlled clinical trial of nafcillin therapy and nafcillin-rifampin therapy. South Med J 79:947–951

    Article  PubMed  CAS  Google Scholar 

  18. Van der Auwera P, Klastersky J, Thys JP, Meunier-Carpentier F, Legrand JC (1985) Double-blind, placebo-controlled study of oxacillin combined with rifampin in the treatment of staphylococcal infections. Antimicrob Agents Chemother 28:467–472

    PubMed  Google Scholar 

  19. Van der Auwera P, Meunier-Carpentier F, Klastersky J (1983) Clinical study of combination therapy with oxacillin and rifampin for staphylococcal infections. Rev Infect Dis 5(Suppl 3):515–522

    Google Scholar 

  20. Vincent F, Ross JB, Dalton M, Wort AJ (1992) A therapeutic trial of the use of penicillin V or erythromycin with or without rifampin in the treatment of psoriasis. J Am Acad Dermatol 26:458–461

    Article  PubMed  CAS  Google Scholar 

  21. Zimmerli W, Widmer AF, Blatter M, Frei R, Ochsner PE; The Foreign-body infection (FBI) Study Group (1998) Role of rifampin for treatment of orthopaedic implant-related Staphylococcal infections; A randomized controlled trial. JAMA 279:1537–1541

    Article  PubMed  CAS  Google Scholar 

  22. Karchmer AW, Archer GL, Dismukes WE (1983) Rifampin treatment of prosthetic valve endocarditis due to Staphylococcus epidermidis. Rev Infect Dis 5(Suppl 3):S543–S548

    PubMed  Google Scholar 

  23. Konig DP, Schierholz JM, Munnich U, Rutt J (2001) Treatment of staphylococcal implant infection with rifampicin-ciprofloxacin in stable implants. Arch Orthop Trauma Surg 121(5):297–299

    Article  PubMed  CAS  Google Scholar 

  24. Swanberg L, Tuazon CU (1984) Rifampin in the treatment of serious staphylococcal infections. Am J Med Sci 287(3):49–54

    Article  PubMed  CAS  Google Scholar 

  25. Consterton JW, Stewart PS, Greenberg EP (1999) Bacterial biofilms: A common cause of persistent infections. Science 284:1318–1322

    Article  Google Scholar 

  26. Peck KR, Kim SW, Jung SI et al (2003) Antimicrobials as potential adjunctive agents in the treatment of biofilm infection with Staphylococcus epidermidis. Chemotherapy 49(4):189–193

    Article  PubMed  CAS  Google Scholar 

  27. Saginur R, St Denis M, Ferris W et al (2006) Multiple combination bactericidal testing of Staphylcoccal biofilms from implant-associated infections. Antimicrob Agents Chemother 50:55–61

    Article  PubMed  CAS  Google Scholar 

  28. Zheng Z, Stewart PS (2002) Penetration of rifampin through Staphylcoccus epidermidis biofilms. Antimicrob Agents Chemother 46:900–903

    Article  PubMed  CAS  Google Scholar 

  29. Falagas ME, Matthaiou DK, Bliziotis IA (2006) The role of aminoglycosides in combination with a beta-lactam for the treatment of bacterial endocarditis: a meta-analysis of comparative trials. J Antimicrob Chemother 57(4):639–647

    Article  PubMed  CAS  Google Scholar 

  30. Bayer AS, Lam K (1985) Efficacy of vancomycin plus rifampin in experimental aortic-valve endocarditis due to methicillin-resistant Staphylococcus aureus: in vitro–in vivo correlations. J Infect Dis 151:157–165

    PubMed  CAS  Google Scholar 

Download references

Transparency declarations

None to declare

Author information

Authors and Affiliations

  1. Alfa Institute of Biomedical Sciences (AIBS), 9 Neapoleos Street, Marousi, Athens, 15123, Greece

    I. A. Bliziotis, F. Ntziora & M. E. Falagas

  2. Department of Pharmacy, Tufts-New England Medical Center, Boston, MA, USA

    K. R. Lawrence

  3. Department of Medicine, Tufts University School of Medicine, Boston, MA, USA

    K. R. Lawrence & M. E. Falagas

  4. Department of Medicine, Henry Dunant Hospital, Athens, Greece

    M. E. Falagas

Authors
  1. I. A. Bliziotis
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. F. Ntziora
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. K. R. Lawrence
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. M. E. Falagas
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to M. E. Falagas.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Bliziotis, I.A., Ntziora, F., Lawrence, K.R. et al. Rifampin as adjuvant treatment of Gram-positive bacterial infections: a systematic review of comparative clinical trials. Eur J Clin Microbiol Infect Dis 26, 849–856 (2007). https://doi.org/10.1007/s10096-007-0378-1

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10096-007-0378-1

Keywords

Search

Navigation